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ABSTRACT CIITA is a master transactivator of the ma-
jor histocompatibility complex class II genes, which are
involved in antigen presentation. Defects in CIITA result in
fatal immunodeficiencies. CIITA activation is also the control
point for the induction of major histocompatibility complex
class II and associated genes by interferon-g, but CIITA does
not bind directly to DNA. Expression of CIITA in G3A cells,
which lack endogenous CIITA, followed by in vivo genomic
footprinting, now reveals that CIITA is required for the
assembly of transcription factor complexes on the promoters
of this gene family, including DRA, Ii, and DMB. CIITA-
dependent promoter assembly occurs in interferon-g-
inducible cell types, but not in B lymphocytes. Dissection of the
CIITA protein indicates that transactivation and promoter
loading are inseparable and reveal a requirement for a GTP
binding motif. These findings suggest that CIITA may be a new
class of transactivator.
The major histocompatibility complex (MHC) class II proteins
DR, DP, DQ, and the associated molecules DM and invariant
chain (Ii) play a central role in the immune response. These
proteins present antigenic peptides on the surface of cells for
recognition by the T cell receptors of class II-restricted T cells
(1). Recently, a novel factor, CIITA, was isolated and shown
to be defective in patients aff licted with one class of bare
lymphocyte syndrome (BLS) (2). BLS is an often fatal genetic
defect, characterized by severe immunodeficiency as a result of
failure to express MHC class II genes. The defects fall into at
least five complementation groups, all of which act at the level
of transcription. Expression of MHC class II molecules in cells
deficient in CIITA can be restored by introducing normal
CIITA (2–4). In normal cells, CIITA expression is induced by
treatment with interferon-g (IFN-g) before induction of MHC
class II, and CIITA alone is sufficient to induce class II DR
expression on the cell surface (3–5). Efficient loading and
presentation of peptides also requires coexpression of the DM
and Ii proteins. These genes are also regulated by CIITA and,
like the MHC class II genes, contain a highly conserved DNA
motif S–X–Y (6–8). Furthermore, when B cells terminally
differentiate into plasma cells, MHC class II expression is lost
concomitantly with CIITA expression (9, 10). CIITA-null mice
fail to express MHC class II on their lymphoid cells (11). Thus,
CIITA appears to be the key switch for turning MHC class II
antigen presentation on or off. Recent evidence has indicated
that CIITA may interact with the basal transcription machin-
ery (12), the coactivator BOB (13), andyor the X-box factor
RFX5 (14). However, the mode of action of CIITA and its in
vivo target have remained elusive.
Changes in promoter assembly or proteinyDNA interactions
can be detected in intact cells by in vivo genomic footprinting
(15). Analysis of the DRA promoter by this technique has
revealed interactions at promoter-proximal transcription fac-
tor binding sites X and Y in both B lymphocytes and IFN-g-
treated cells (16, 17). The Ii and DMB promoters show similar
interactions at the their X and Y sites (18–20). Promoter
assembly has a primary dependence on the Y box to initiate
factor binding in IFN-g responsive cells and an interdepen-
dence between the X1 and X2 binding activities (21, 22).
However, IFN-g does not induce the X and Y box binding
factors, but rather induces expression of CIITA, which does not
bind to DNA directly. Importantly, CIITA can serve as a
transactivator when artificially tethered to a basal promoter
(23, 24). In this report, we demonstrate that CIITA is required
for the assembly of transcription factors specifically on the
MHC class II promoters and that the promoter assembly
function and transactivation are inseparable.
EXPERIMENTAL PROCEDURES
Cell Culture and Transient Transfection. U373-MG is a
glioblastoma multiforme cell line that expresses low basal
levels and high IFN-g-induced levels of MHC class II antigens
(25). These cells were maintained in McCoys 5A medium with
10% fetal calf serum (FCS), 2 mM glutamine, 100 units of
penicillin, and 100 mgyml streptomycin. The 2fTGH cell line
is a derivative of human HT1080 fibrosarcoma cells (American
Type Culture Collection). G3A is a chemically derived mutant
of 2fTGH selected for loss of MHC class II expression (26) and
it is defective in CIITA expression (3). 2fTGH and G3A cells
were grown in DMEM containing 10% FCS as described (26).
Stable Cell Line Transfection and Selection. Each CIITA
expression construct (20 mg) was introduced independently
into 5 3 105 G3A cells by standard calcium phosphate pre-
cipitation method (3), and the cells were allowed to proliferate
for 3 weeks. The cells were then positively selected for MHC
class II DR surface expression by using the DR-specific
antibody L243 attached to magnetic beads (Dynal, Lake
Success, NY). The polyclonal cell population was occasionally
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monitored for continued DR expression and reselected with
magnetic beads. The CIITA expression constructs were pos-
itively selected with 250 unitsyml hygromycin, beginning 24–36
hr after transfection. Individual resistant colonies were visible
after 2–3 weeks, at which time the cells were pooled and
analyzed. Cell lines were always maintained in the appropriate
drug except when harvested for analysis of chloramphenicol
acetyltransferase activity.
Constructs. The CIITA expression construct
pcDNA3.FLAG.CIITA8 contains the CIITA coding sequence
driven by a cytomegalovirus promoter in the vector pcDNA3
(Invitrogen) and includes a neomycin resistance marker. An
eight amino acid FLAG epitope (DYKDDDDK) is inserted
before the first methionine in CIITA. The CIITA expression
construct, pREP4.FLAG.CIITA8 is the same as above, except
that CIITA is carried in the pREP4 episomal vector (Invitro-
gen) and, thus, has a hygromycin resistance marker. All of the
mutant forms of CIITA used in this report are derivatives of
the pREP4.FLAG.CIITA8 construct. These plasmids and the
construction of the mutants are described in detail elsewhere
(27), except for the RJ-CIITA expression construct, which was
described previously (28).
In Vivo Footprinting. In vivo methylation by dimethyl sulfate
of cells and the DNA preparation were as described (29). The
ligation-mediated PCR-amplified in vivo genomic footprinting
was described originally by Mueller and Wold (15) and mod-
ified by Wright and Ting (17). The primers used to reveal the
endogenous DRA promoter were as described previously (17).
The primer set used to reveal the Ii proximal promoter upper
strand have been described (18, 22). The upper strand of the




TGAC-39. The TAP1 promoter region was analyzed in vivo
with the R124D primer set as described (30).
RESULTS
Transactivation by CIITA of the MHC class II DRA promoter
requires the S–X–Y motifs in B lymphocytes (23). These motifs
are also required for activation by CIITA in IFN-g inducible
cell types (K.-C.C., unpublished observation). Because CIITA
does not have a recognizable DNA binding motif, it is possible
that CIITA interacts directly with transcription factors bound
to the S–X–Y motif and not with the DNA. However, these
interactions have been difficult to demonstrate in intact cells.
Recent evidence from experiments using a yeast one-hybrid
system has suggested an interaction between CIITA and
recombinant X box factor RFX5 (14). We now address the role
of CIITA in a physiologically normal environment, where
chromatin may help to regulate the access of factors to the
DNA. By using in vivo genomic footprinting, we have evaluated
the importance of CIITA for the assembly of factors on the
promoters in intact cells.
CIITA Is Required for Promoter Complex Assembly in Vivo.
The fibrosarcoma cell line 2fTGH expresses very low levels of
MHC class II on the cell surface, but expression is strongly
induced by IFN-g (3, 26). In vivo genomic footprinting of the
MHC class II promoter DRA reveals proteinyDNA interac-
tions at the X1, X2, and Y box domains (Fig. 1, lanes 1 and 2).
Both guanine residues of the Y box are protected by 50–70%,
whereas single guanine residues in the X1 and X2 boxes are
protected nearly completely (open arrows). Increased sensi-
FIG. 1. CIITA mediates in vivo promoter occupancy of MHC class II and associated genes. In vivo footprint of the DRA upper strand in 2fTGH
and CIITA-deficient G3A cells. As indicated above each lane, the cells were induced with IFN-g or stably express CIITA from an integrated
transgene. The functional promoter elements are marked on the left. Solid arrows indicate enhancements; open arrows indicate protections; in vitro
indicates control, deproteinized methylated genomic DNA in vitro. IFN-g-induced 2fTGH cells display strong protections and enhancements at the
X1 and X2 boxes and substantial protections at the Y box (lanes 1 and 2). Before IFN-g treatment, the same, but less intense, interactions are
observed [data not shown and Wright and Ting (17)]. G3A cells have a bare DRA promoter unless CIITA is introduced (lanes 3–6). In vivo genomic
footprinting was done as described on at least three different DNA preparations, analyzed at least twice each. Cells were treated with recombinant
IFN-g at 500 units per ml for 48 hr before harvest.
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tivity of three guanine residues is also revealed (solid arrows).
Residues in the lower strand of the X box region are also
protected (data not shown). The S box does not show any
changes. The same pattern of interactions was detected pre-
viously in HeLa and the glioblastoma U373-MG cells and the
strength of the interaction is increased upon IFN-g treatment
(17, 32).
The in vivo footprint pattern of DNA from a CIITA-negative
cell line was analyzed to decipher the effect of CIITA on the
assembly of the DRA promoter. G3A is a CIITA-negative
mutant cell line derived from 2fTGH (3), and it did not show
significant protection over the X1, X2, and Y elements on
either the upper strand (Fig. 1, lanes 3 and 4) or the lower
strand (data not shown) even after IFN-g treatment. Stable
expression of CIITA into G3A cells restored promoter occu-
pancy in vivo, providing direct evidence that CIITA results in
promoter loading in vivo (Fig. 1, lanes 5 and 6). The contacts
observed were similar to those in IFN-g-treated 2fTGH cells
and were not increased further by treatment with IFN-g (data
not shown). The site of CIITA integration into the genome did
not artifactually cause DRA promoter loading, because iden-
tical results were obtained when CIITA was introduced as an
episome (see below and Fig. 2C). These findings demonstrate
that CIITA is required for transcription factor assembly on
MHC class II promoters in response to IFN-g.
In Vivo Promoter Assembly and Transactivation Functions
of CIITA Map to the Same Domains of the Protein. To map the
domains of CIITA required for promoter assembly, a series of
CIITA mutant proteins were produced. Each was introduced
stably into the CIITA-negative G3A cell line and both in vivo
promoter assembly and the activation of endogenous MHC
class II genes were analyzed. In the initial experiments, four
mutant forms of CIITA were examined (Fig. 2A). RJ, isolated
from the B lymphoblastoid cell line RJ2.2.5, codes for only the
first 336 residues (28). RJ2.2.5 does not express MHC class II
because of the defective CIITA, but the DRA promoter is fully
occupied in vivo (16). Mutant 1–1089, with a deletion of only
the carboxyl-terminal 41 residues, partially disrupts a leucine
repeat motif. Mutant D132–212 contains an internal deletion
of the proline-rich domain and mutant GTP3(DSKAD) has a
four residue change in a GTP binding motif (27). The four
mutant forms of CIITA, the wild-type control, and the empty
vector were stably introduced as episomes into G3A cells. Cell
surface expression of the MHC class II DR protein was
measured in each stable cell line by fluorescence-activated cell
sorting. Untransfected G3A cells or G3A cells transfected with
the empty vector did not express detectable levels of DR (Fig.
2B). Wild-type CIITA induced an increase of more than
100-fold in cell surface DR expression. Deletion of either the
carboxyl-terminal two-thirds of the protein (RJ-CIITA) or just
the 41 carboxyl-terminal residues (1-1089) abolished cell sur-
face expression. The proline-rich domain is not required to
activate MHC class II expression because D132–212 is func-
tional, with a level of cell surface DR similar to that induced
FIG. 2. DRA transactivation and promoter assembly in cells expressing mutant forms of CIITA. (A) CIITA mutants. A, acidic domain; P,
proline-rich domain; S, serine-rich domain; T, threonine-rich domain; GTP indicates the three homologies to a GTP binding motif; BLS2D indicates
the region deleted in BLS patient line BLS2. The RJ protein was isolated from the class II-negative cell line RJ2.2.5. Transactivation indicates
whether that form of CIITA activated DRA transcription in a cotransient transfection assay. 1, Full activation compared with wild-type CIITA;
2, absolutely no activity. (B) Cell surface expression of DR in G3A cells stably expressing the indicated form of CIITA was detected by
fluorescence-activated cell sorter. Solid profile shows DR expression in the test cells; open profile is the DR expression in G3A cells stably
transfected with empty vector. Only the wild-type and D132–212 CIITA proteins were able to transactivate. Similar levels of CIITA proteins were
expressed in each stably transfected cell line, as detected by Western analysis with the FLAG epitope tag antibody (IBIyKodak). (C) In vivo footprint
analysis of DRA promoter occupancy. Cell lines analyzed are as in B and p4 indicates the cell line with the empty vector. Footprinting and lane
markings are as in Fig. 1. Only in the wild-type (lane 3) and D132–212 (lane 6) cell lines are protections and enhancements clearly found within
the X1, X2, and Y boxes. The other mutant CIITA proteins do not promote factor binding.
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by wild-type CIITA. Interestingly, the relatively minor four
amino acid change in GTP3(DSKAD) completely abolished
transactivation by CIITA. The ability of these mutant forms to
transactivate the DRA-CAT reporter gene construct in tran-
sient assays was also examined. Each form of CIITA that does
not activate endogenous gene expression also does not induce
transcription in a transient expression assay, whereas both the
wild-type and D132–212 proteins do activate transcription (ref.
27, and summarized in Fig. 2 A). Similar levels of CIITA
protein were expressed in each stably transfected cell line, as
detected by Western blot analysis (data not shown).
The in vivo promoter occupancy of the DRA gene was
examined to determine whether the promoter assembly func-
tion of CIITA could be separated from gene activation and DR
cell surface expression. Fig. 2C shows the in vivo analysis of the
same stable lines as in Fig. 2B. Wild-type and D132–212 CIITA
proteins, when stably expressed from an episome, induce DRA
promoter occupancy at the X1, X2, and Y boxes (compare
lanes 3 and 6 with lane 2). This result is consistent with the
normal levels of cell surface DR present in these lines. The
three CIITA forms that fail to induce cell surface DR are not
functional for DRA promoter assembly: none of the protec-
tions or enhancements are detected in these lines (lanes 4, 5,
and 7). These findings indicate that the requirement for CIITA
in transactivation and its requirement for promoter assembly
are encoded by overlapping regions within CIITA and are
potentially identical.
CIITA also Promotes the Assembly of the Ii and DMB
Promoters, but Not the TAP1 Promoter. The ability of CIITA
mutant forms to drive the assembly of factors on the Ii and
DMB promoters was examined next. The Ii promoter consists
of a distal domain containing the S–X–Y conserved elements
and a proximal domain containing a GC box and second Y box.
The lower strand of the distal Ii domain is displayed in Fig. 3A.
Strong protections were observed within the X box when
wild-type CIITA was introduced into CIITA-deficient G3A
cells (lanes 2 and 3). The two guanine residues in the Y box
were also substantially protected. Similar to the activity of
CIITA on the DRA promoter, the RJ, 1–1089, and
GTP3(DSKAD) mutant proteins do not promote factor bind-
ing to the S–X–Y domain of Ii (lanes 4, 5, and 7). The
proline-rich deletion D132–212, however, was competent to
activate Ii promoter loading in the distal region (lane 6). Ii also
uses a second promoter-proximal domain for full transcrip-
tional activation. A direct correlation was observed between
occupancy of the distal region and the proximal region. The
proximal region GC and second Y boxes were only occupied
when either the wild-type or D132–212 CIITA proteins were
present (data not shown). The three transcriptionally inactive
forms of CIITA failed to promote factor binding. These
findings indicate that CIITA is required for the assembly of
factors on the Ii promoter, not only on the conserved S–X–Y
domain but also across the entire 270 bp promoter.
The DMB promoter was also examined to test the impor-
tance of CIITA for promoter assembly of nonclassical MHC
class II genes. This promoter has a similar S–X–Y domain (20,
33). In vivo footprinting of the upper strand of the DMB
promoter revealed that expression of either wild-type or
D132–212 CIITA were necessary to observe occupancy of the
X and Y domains in G3A cells (Fig. 3B, lanes 2 and 3). Similar
to the DRA and Ii promoters, the transcriptionally inactive
forms of CIITA (lane 4) did not induce assembly of transcrip-
tion factors on the DMB promoter. These findings indicate
that CIITA is required for transcription factor assembly on all
of the MHC class II and associated promoters.
To exclude the possibility that CIITA serves as a general
chromatin derepressor or nonspecifically disrupts chromatin
structure at the MHC class II locus, thus allowing sequence-
FIG. 3. Invariant chain and DMB promoter occupancy in cells expressing mutant CIITA proteins. (A) Invariant chain distal promoter region.
Strong protections of the X and Y elements are seen in the cells expressing wild-type and D132–212 CIITA proteins (lanes 3 and 6). The contacts
are the same as shown previously in B cells (18, 19) and were confirmed at least four times. (B) DMB promoter region. G3A cells expressing wild-type
or GTP3(DSKAD) CIITA or the empty vector p4 were examined by in vivo footprinting of the DMB promoter upper strand. The strongest
protections are on the X1 box at nucleotide 2136 and on the Y box at nucleotide 299. The lane markings are as described in Fig. 2C.
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specific transcription factors to bind, we examined the TAP1
promoter. TAP1, an unrelated gene located within the MHC
class II locus, is not induced by CIITA, but is activated by
IFN-g (31). Studies in our laboratory have characterized this
promoter and demonstrated both functional GC boxes and
NF-kB sites (30). The NF-kB site is occupied only after
activation of NF-kB, for example by tumor necrosis factor-a.
In addition, the TAP1 promoter contains an interferon re-
sponse factor element, which binds to IRF-1 in response to
IFN-g (34–36). In the absence of CIITA, the GC box of the
TAP1 promoter was clearly occupied (Fig. 4, lanes 1 and 2).
Neither the NF-kB site nor the interferon response factor
element site were occupied, because the cells were not treated
with either IFN-g or tumor necrosis factor-a. CIITA does not
alter TAP1 promoter occupancy (lane 3). These observations
demonstrate that the ability of CIITA to activate promoter
assembly is specific for MHC class II and associated genes.
DISCUSSION
The MHC class II gene family is coordinately regulated, and
expression is restricted to a small group of antigen-presenting
cells. Each of the promoters contains the highly conserved
trimeric motif S–X–Y, which is required for expression. Ex-
tensive studies of these promoter elements has led to the
characterization andyor cloning of the transcription factors
bound to them (6, 8, 37). However, these factors do not
account for the cell type-specific control and cytokine induc-
tion of MHC class II expression. The novel transactivator
CIITA mediates MHC class II activation (2–4). Although it
has been clearly demonstrated that CIITA is required for
MHC class II gene transcription, the mode of its action has
remained elusive. The findings presented here now demon-
strate that CIITA is absolutely required for the specific
assembly of MHC class II promoter complexes in response to
IFN-g, but not on other promoters in the region. This agrees
with the suggestion of a previous study that showed a corre-
lation between the lack of CIITA in thymic epithelial cells and
a closed promoter (38). In vivo footprinting has been invalu-
able for understanding gene regulation in living cells. We and
others have used it to examine the MHC class II promoters (16,
17). In B cells, which express the MHC class II genes consti-
tutively, strong occupancy of the X1, X2, Y, and octamer sites
is observed. In untreated IFN-g-inducible cells, the X1 and X2
boxes are occupied only weakly, but then become fully occu-
pied after IFN-g treatment (17). In vivo binding at the Ii
promoter is also activated by IFN-g, but before induction the
Ii promoter is completely bare (18).
The role of CIITA in activating MHC class II promoter
loading was analyzed in the IFN-g-inducible cell line 2fTGH
and in the mutant cell line G3A in which CIITA is not
expressed. In the parental cell, CIITA expression alone was
sufficient to promote strong occupancy of the X1, X2, and Y
boxes. In the CIITA-deficient G3A cells, the DRA, Ii, and
DMB promoters are bare and introduction of CIITA recon-
stituted normal promoter loading. This result is surprising and
contrasts with findings where MHC class II-negative B cells
with defective CIITA expression have occupied MHC class II
promoters in vivo. Based on the B cell data, it is the general
belief that CIITA does not alter promoter assembly. Indeed,
examination of the B cell lines RJ2.2.5, RM3, and BLS-2, each
members of the CIITA-defective complementation group,
reveals a fully occupied DRA promoter (16) with only a
minimal alteration in affinity (39). The Ii promoter is also fully
loaded with its transcription factors in RJ2.2.5 cells (M.L.,
unpublished observations). RJ2.2.5 is now known to have a
severe deletion of CIITA that prevents transactivation. When
the deleted form of CIITA from RJ2.2.5 was expressed stably
in G3A cells, there was no enhancement of DRA, Ii, or DMB
promoter loading and no transcriptional activation. This dem-
onstrates that the DRA promoter assembly differences ob-
served between G3A and RJ2.2.5 are not due to expression of
this deleted CIITA protein in RJ2.2.5. Thus, in cells that
require IFN-g to induce MHC class II transcription, CIITA is
necessary to assemble the promoter complex. However, in B
cells with constitutive MHC class II transcription, loss of
CIITA does not lead to a loss of promoter assembly, only to a
loss of transcription. This finding clearly indicates a difference
between how B cells and IFN-g-inducible cells assemble the
MHC class II promoter. Importantly, it also defines a previ-
ously undescribed function of CIITA in promoter complex
assembly.
Previous reports from our laboratory and others have also
shown a difference between promoter assembly in B cells and
IFN-g-inducible cells (21, 22, 38, 40). Our findings with the
inducible cells demonstrated a complete dependence on the
NF–YyY box interaction for any of the other interactions to
occur in vivo. However, by using the same methodology, B cells
displayed no interdependence for binding among the DRA
promoter factors. One possibility is that binding of the B cell
factor OTF-2 on the DRA promoter modifies the need for
CIITA to drive promoter occupancy. This would be consistent
with a recent report showing that the OTF coactivator BOB
functions synergistically with CIITA, even in the absence of an
OTF-2 DNA binding site (13). Alternatively, the X or Y box
factors may be modified differently in the two cell types and
thus may have different requirements for CIITA. Recent
results have shown that the X box factor RFX5 is phosphor-
ylated. However, CIITA does not appear to alter the overall
phosphorylation state of RFX5 (41). Thus, CIITA has a dual
role in MHC class II-inducible cells in assembling factors on
FIG. 4. CIITA does not effect promoter occupancy of the MHC-
encoded, nonclass II gene TAP1. The same cell lines analyzed in Fig.
2 were examined for TAP1 promoter binding in vivo. Only the GC box
is occupied in these cells, and the in vivo footprint is not altered by
CIITA (lanes 2 and 3). The interferon response factor element is not
occupied before or after introduction of CIITA. The contacts shown
here are similar to those previously reported in HeLa cells (30).
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the promoters and in transactivating, whereas in B lympho-
cytes only transactivation is required.
Homology studies of the CIITA protein have yielded few
clues to its activity. However, a putative GTP binding domain
consisting of three motifs has been identified and mutated, and
each motif has been found to be critical for transactivation
(27). This is an intriguing observation because only a few
transactivators have been shown to bind ATP and none bind
GTP. The SwiySnf complex, which is functionally and physi-
cally associated with the polymerase II holoenzyme, requires
ATP, disrupts chromatin, and activates transcription (42).
SwiySnf appears to be recruited to all functional promoters
through polymerase II, but affects only some promoters.
Conversely, CIITA represents a highly specific regulator only
of genes in the MHC class II pathway. A few other transacti-
vators, such as GAGA, the glucocorticoid receptor, and HNF-
3-like factors have been shown to disrupt the local structure of
chromatin, allowing binding of additional transcription factors
(43). However, in contrast to CIITA, each of these factors has
an intrinsic DNA binding activity and functions by direct
association with the DNA of the promoter.
This report shows that CIITA is required in vivo for pro-
moter assembly in IFN-g-inducible cells, but not in B cells. In
both cell types, CIITA is absolutely required for transactiva-
tion. The structure and mode of action of CIITA suggest that
it may define a new class of transcriptional coactivators.
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